RTTNews盘后汇总多只生物科技股当日大涨及业绩/临床进展

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
TODAY'S TOP STORIES
By
Prabha Kurup
✉
|
Published:
7/30/2026 11:25 PM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others.
Read on…
GCTK's LT-100 Program Moves Forward
Glucotrack Inc. (
GCTK
) led Thursday's gainers after its subsidiary, Lokahi Therapeutics Inc., announced progress in the development strategy for LT-100.
LT-100 is a novel, non-narcotic therapy derived from purified honeybee venom and is being studied for the treatment of inflammation and pain, including in patients with osteoarthritis.
The company is evaluating whether the current administration method - requiring up to 15 intradermal (ID) injections per treatment visit - can be simplified to a single subcutaneous (SC) injection per visit, potentially improving patient convenience and treatment efficiency.
Glucotrack expects to begin clinical evaluation of the new administration approach as early as the fourth quarter of 2026, with initial data potentially available in the first half of 2027.
GCTK closed Thursday's trading at $0.78, up 173.68%.
NUWE's Aquadex Therapy Gains Peer-Reviewed Recognition
Shares of medical
technology
company Nuwellis Inc. (
NUWE
) surged more than 135% after the company announced that the peer-reviewed medical journal Frontiers in Pediatrics had accepted a new single-center retrospective study highlighting Epoprostenol as an alternative anticoagulation strategy for its Aquadex ultrafiltration therapy.
The study's acceptance in a respected peer-reviewed journal represents another important milestone in the expanding clinical evidence supporting Aquadex therapy in pediatric critical care, said Nuwellis CEO Mike McCormick.
Aquadex ultrafiltration therapy is designed to remove excess fluid from the body using the Aquadex FlexFlow and Aquadex SmartFlow systems in patients with fluid overload who have not responded adequately to standard diuretic therapy. Also known as hypervolemia, fluid overload can result from conditions such as heart failure, kidney failure, and cirrhosis, among other diseases.
NUWE closed Thursday's trading at $4.45, up 135.45%.
BHC lifts FY'26 Outlook
Bausch Health Companies Inc. (
BHC
) was one of the top gainers on Thursday, following its second quarter 2026 financial results and revised guidance.
The total consolidated revenue was $2.85 billion for the second quarter of 2026, up 13% from $2.53 billion in the year-ago quarter. Consolidated adjusted net income attributable to Bausch Health was $476 million, or $1.26 per share in Q2, 2026, up from $335 million, or $0.90 per share, in the year-ago quarter.
The company also raised its full-year 2026 revenue outlook to $10.790 billion - $11.040 billion from its previous guidance of $10.670 - $10.920 billion.
BHC closed Thursday's trading at $6.03, up 28.85%.
LUNG Posts Narrower Q2 Loss
Pulmonx Corp. (LUNG), which
markets
minimally invasive treatments for lung diseases, reported weaker second-quarter 2026 revenue but a narrower net loss.
Total worldwide revenue in Q2 2026 declined 5% to $22.8 million from $23.9 million in the second quarter of 2025 (down 6% on a constant-currency basis). However, net loss improved to $10.1 million, or $0.24 per share, from $15.2 million, or $0.38 per share, a year earlier.
For the full year, the company continues to expect revenue in the range of $90 million to $92 million, compared with 2025 revenue of $90.5 million.
LUNG closed Thursday's trading at $1.61, up 28.80%.
CORT Turns Heads
Shares of Corcept Therapeutics Inc. (
CORT
) touched a new high on Thursday after the company reported strong second-quarter 2026 results.
Net income increased to $43.0 million, or $0.36 per share in Q2, 2026, from $35.1 million, or $0.29 per share, a year earlier. Revenue climbed to $256.1 million in the second quarter of 2026 from $194.4 million in the prior-year quarter. The Q2, 2026 revenue included $208.6 million in sales of Korlym and its authorized generic, as well as $47.6 million from Lifyorli, which was launched following its
FDA approval
in March 2026.
For full-year 2026, Corcept raised its revenue forecast range to $1.1 billion-$1.2 billion, up from its previous guidance of $950 million-$1.05 billion and well above 2025 revenue of $761.4 million.
CORT closed Thursday's trading at $118.32, up 27.29%.
NEOG Hits New High
Neogen Corp. (NEOG) touched a 52-week high of $11.56 in intraday trading on Thursday after the company announced its fiscal fourth-quarter and full-year 2026 results and issued financial guidance for the first quarter and full fiscal year 2027.
The company provides a broad portfolio of products and solutions across the Food Safety, Livestock, and Pet Health & Wellness markets.
Revenues for the fourth quarter were $225.3 million, compared to $225.5 million in the prior year. Adjusted Net Income for the fourth quarter was $18.7 million, or $0.09 per share, compared to $11.3 million, or $0.05 per share, in the prior year period.
For the first quarter of fiscal 2027, Neogen expects revenue of $207 million to $209 million, compared with $209.2 million in the first quarter of fiscal 2026. For fiscal 2027, the company forecasts revenue of $880 million to $885 million, up from $870.4 million in fiscal 2026.
NEOG closed Thursday's trading at $11.53, up 22.26%.
Did you know?
The expression "Alice in Wonderland" is often used to describe something unusual, surreal, or dreamlike.
Interestingly, there is also a rare neurological condition called Alice in Wonderland Syndrome, which affects how a person perceives their own body, the world around them, or both. This temporary condition, which may last only minutes or hours, can distort a person's sense of size and proportion, causing parts of the body to feel unusually large (partial macrosomatognosia) or unusually small (partial microsomatognosia). In some cases, the sensation can involve the entire body, making it feel abnormally tall (total macrosomatognosia) or unusually short (total microsomatognosia). (Source: Cleveland Clinic)
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Previous Story
Next Story
Latest Updates on Middle East War
U.S. Dollar Slides Amid Uncertainty Over Fed's Moves, Economic Data Releases
July 31, 2026 17:00 ET
Canadian Stocks Slide Amid Persisting Middle East Tensions, GDP Data Release
July 31, 2026 16:31 ET
Crude Oil Surges As U.S.-Iran Conflict Keeps Strait Of Hormuz Crisis Alive
July 31, 2026 14:40 ET
Gold Surges As Investors Parse Fed's Interest Rate Decision Amid Middle East Tensions
July 30, 2026 13:37 ET
Gold Slumps Amid Diminishing Signs Of Near-Term U.S.-Iran Truce, Profit Taking
July 31, 2026 13:36 ET
View More
FDA Decisions August 2026: Key PDUFA Dates Biotech Investors Are Watching | RTT BIOTECH NEWS
July 30, 2026 04:24 ET
The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment.
In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
View More Videos
RELATED NEWS
Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR
Corcept Therapeutics Q2 Profit Rises; Raises FY26 Outlook
Will Corcept Therapeutics Reclaim The $100 Mark Again?
Returns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio?
Latest Updates on COVID-19
Editor's Pick
Most Read
Most Emailed
Colgate-Palmolive Lifts FY26 Adj. Earnings View, Despite Weak Q2 Profit; Stock Down
July 31, 2026 08:06 ET
Xerox Stock Up 26% On Q2 Turnaround, Raised FY26 Outlook
July 30, 2026 08:42 ET
Automatic Data Processing Sees Growth In FY27 - Update
July 29, 2026 07:20 ET
GE HealthCare Stock Up 13% On Strong Q2 Profit & Orders, Positive Outlook
Boston Scientific Trims FY26 Outlook - Update
July 29, 2026 06:50 ET
Humana Q2 Profit Climbs, Cuts FY26 EPS Outlook, Backs Adj. Earnings, Revenue View; Stock Down
July 29, 2026 06:44 ET
Boeing Q4 Net Loss Narrows, Revenues Rise 8%
July 28, 2026 08:03 ET
Coca-Cola Boosts FY26 Outlook - Update
July 28, 2026 07:24 ET
UPS Lifts FY26 Outlook, Despite Weak Q2 Profit
July 28, 2026 07:09 ET
Philips Stock Drops On Weak Q2 Orders, Despite Profit Growth, Positive Outlook
July 28, 2026 06:01 ET
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
July 27, 2026 04:19 ET
Ecolab Raises 2026 Earnings Guidance
July 28, 2026 08:33 ET
ProStar Holdings Appoints Michael Wolff As CEO, Succeeding Founder Page Tucker; Shares Down
July 27, 2026 08:34 ET
Expand Energy To Buy Twin Eagle For $1.25 Bln
July 27, 2026 07:49 ET
Carpenter Technology CEO Brian Malloy Passes Away; Tony Thene Named CEO
July 27, 2026 08:18 ET
Sanofi Q2 Net Profit Plunges, Business Profit Climbs On Strong Sales; Lifts FY26 Outlook
July 30, 2026 02:02 ET
Gildan Activewear To Sell HanesBrands Australia For A$700 Mln; Lifts Annual Adj. Income Outlook
July 30, 2026 08:31 ET
Argenx To Buy Forte Biosciences In Around $2.2 Bln Cash Deal; Forte Biosciences Shares Climb
July 27, 2026 01:24 ET
Virtuix Says Tesla Buys Simulation System For Optimus Robots; Shares Tumble
July 27, 2026 11:17 ET
LG Energy Solution Q2 Operating Income Falls
July 30, 2026 01:06 ET
Perfect Corp. Q2 Profit Climbs
July 27, 2026 06:39 ET
Everbright Digital Prices Public Offering Of 4.293 Mln Ordinary Shares At $1.88/Shr
July 26, 2026 12:05 ET
Rocket Lab Awarded $266 Mln Multi-launch Contract With U.S. Space Force, Shares Up
July 27, 2026 06:46 ET
Samsung And Broadcom Announce $200 Bln+ Collaboration In Memory And Foundry For Next-Gen AI
July 26, 2026 21:45 ET
Bank Of Hawaii Corporation Profit Rises In Q2
July 27, 2026 06:56 ET
Raffles Medical Group Ltd H1 Income Falls
July 27, 2026 00:41 ET
First Farmers And Merchants Corporation Reports Increase In Q2 Profit
July 27, 2026 07:07 ET
NAGAWA CO Ltd Bottom Line Rises In Q1
July 27, 2026 00:49 ET
HBT Financial, Inc. Q2 Income Advances
July 27, 2026 07:14 ET
Brown-Forman Rejects Sazerac's Unsolicited Proposal
July 27, 2026 00:57 ET
Lakeland Financial Corp. Reports Rise In Q2 Profit
July 27, 2026 07:21 ET
Baker Hughes Q2 Profit Down, Orders Climb; Expects To Meet Mid Point Of FY26 View; Stock Gains
July 27, 2026 01:00 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap